The ultra-pure animal-free chitosan


KiOmedine® is a pioneering platform of ultra-pure non-animal biopolymers for therapeutic innovations. It enables to design safe and patent systems for medical devices, cellular therapy, tissue engineering and drug delivery: 100% animal-free, outstanding traceability, high control on molecular characteristics, high purity and safety profrile.

KitoZyme injects the right solution into your business with its ultra-pure GMP biopolymers range called KiOmedine®.

Partnering with KitoZyme and injecting KiOmedine® technology into your pharmaceutical or medical device business will give you the competitive edge you need by:

Injecting pioneering developments into your business

Cut short the lead time between proof-of-concept, pilot study and full market launch by relying on KitoZyme’s expertise. With the help of our huge know-how and our strong customer support, your development work will land right on time with no surprises allowing you to stay ahead of the competition.


KitoZyme's technology enables a tight management of the molecular characteristics of chitosan, and to offer a range of 4 different molecular weight of ultra-pure GMP chitosan.

The KiOmedine®range is now distributed by Sigma-Aldrich for research purposes. Click here to order samples and find detailed information : Sigma-Aldrich website

Injecting innovation into your R&D

If your R&D needs efficient biopolymers then KiOmedine® is right for you. Thanks to the reliable supply of our ultra-pure non-animal sourced chitosan with high safety profile and our skilled researcher’s expertise, you will safely fast-track your projects.

Ultra-pure animal-free GMP chitosan

KiOmedine® is a pioneering platform of ultra-pure biopolymers for therapeutic innovations.

KiOmedine® offers you unique features:

  • Wide range of top performances & functionalities
  • Easiness of screening
  • 100% animal-free
  • High purity and safety profile: Low bioburden, Endotoxin-free
  • Outstanding traceability
  • Strong documentation
  • Produced according to a fully validated cGMP process, in KitoZyme’s ISO7/ISO8 facilities in Europe.

Safe and reliable KiOmedine®’s GMP biopolymers are ideal for:

  • Wound healing and hemostasis
  • Biosurgery and Ophtalmology
  • Scaffold and cell therapy
  • Drug delivery and vaccines

KitoZyme offers…


KitoZyme has designed KiOmedine®-Csu suitable for all use including injectables and implantables.

KiOmedine-CsU® is world’s first ultra-pure chitosan, produced from a non-animal source, in accordance with a cGMP patented process in KitoZyme’s ISO7/ISO8 facilities. A recent development in its technology has enabled the production of a larger molecular weight biopolymer, thereby broadening the KiOmedine-CsU® range and giving access to new functionalities of the biopolymer for therapeutic innovation. These new features are immensely beneficial when high mechanical properties, high viscosity at a lower concentration and fast degradation rates are sought.

The average molecular weight of KiOmedine-CsU® is now in the range of 30,000 to 200,000, with narrow polydispersity and high batch-to-batch consistency. This extended range gives the opportunity to medical and pharmaceutical companies to screen variable molecular characteristics for optimum and consistent performance, providing opportunities for customized specification and greater differentiation of the final formulations.


KitoZyme has designed KiOmedine®-T suitable for topical and oral care(high chitosan content, highly controlled microbial burden).

Our ultra-pure chitosan & our references

The following articles screen several formulations based on KiOmedine-CsU®

1. Development of a Chitosan Nanofibrillar Scaffold for Skin Repair and Regeneration

Tchemtchoua VT, Atanasova G, Aqil A, Filée P, Garbacki N, Vanhooteghem O, Deroanne C, Noël A, Jérome C, Nusgens B, Poumay Y, Colige A.

Source - Laboratory of Connective Tissues Biology, University of Liège, Liège, Belgium.

The final goal of the present study was the development of a 3-D chitosan dressing that would shorten the healing time of skin wounds by stimulating migration, invasion, and proliferation of the relevant cutaneous resident cells. Three-dimensional chitosan nanofibrillar scaffolds produced by electrospinning were compared with evaporated films and freeze-dried sponges for their biological properties. The nanofibrillar structure strongly improved cell adhesion and proliferation in vitro. When implanted in mice, the nanofibrillar scaffold was colonized by mesenchymal cells and blood vessels. Accumulation of collagen fibrils was also observed. In contrast, sponges induced a foreign body granuloma. When used as a dressing covering full-thickness skin wounds in mice, chitosan nanofibrils induced a faster regeneration of both the epidermis and dermis compartments. Altogether our data illustrate the critical importance of the nanofibrillar structure of chitosan devices for their full biocompatibility and demonstrate the significant beneficial effect of chitosan as a wound-healing biomaterial.

PMID: 21761871 [PubMed - indexed for MEDLINE]

2. Biophysical properties of chitosan/siRNA polyplexes: Profiling the polymer/siRNA interactions and bioactivity

Holzerny P, Ajdini B, Heusermann W, Bruno K, Schuleit M, Meinel L, Keller M

Source - Novartis Pharma AG, Technical Research & Development (TRD), CH-4002 Basel, Switzerland

Chitosans are naturally occurring polymers widely used in life science to mediate intracellular uptake of nucleic acids such as siRNA. Four chitosans of fungal origin (Agaricus bisporus; molecular weights MW=44, 63, 93 and 143 kDa) were used in this study and profiled for size, viscosity and hydrodynamic radius using gel permeation chromatography (GPC). Polyplexes made of these chitosans and siRNA were developed and optimized for transfection efficacy in vitro. The characteristics of these polyplexes were low chitosan:siRNA ratios (4-8; N:P) similar positive zeta potential (20-30 mV) and comparable particle sizes (about 150 nm). Endogenous luciferase reporter gene down-regulation in human epithelial H1299 cells at nanomolar concentrations (37.5-150 nM) was significantly stronger for the lower molecular weight chitosans. The impact of these low N:P polyplexes on the cellular viability was minimal also at 150 nM. To help develop an understanding of these differences, an energetic profile of the molecular interactions and polyplex formation was established by isothermal titration calorimetry (ITC). The four polyplexes exhibited strong binding enthalpies delta H(bind)(-84 to -102 kcal/mol) resulting in nanomolar dissociation constants. Intracellular trafficking studies using rhodamine labeled siRNA revealed that polyplexes made from smaller MW chitosans exhibited faster cellular uptake kinetics than their higher MW counterpart. Transmission electron microscopy and small angle X-ray scattering studies (SAXS) revealed that the 44 kDa derived polyplexes exhibited regular spherical structure, whereas the 143 kDa chitosan polyplex was rather irregularly shaped. With regards to adverse effects these low N:P chitosan/siRNA formulations represent an interesting alternative to so far reported chitosan polyplexes that used vast N:P excess to achieve similar bioactivity.

Copyright © 2011 Elsevier B.V. All rights reserved.

PMID: 21884740 [PubMed - indexed for MEDLINE]

Academic Research

KitoZyme's technology enables a tight management of the molecular characteristics of chitosan, and to offer a range of 4 different molecular weight of ultra-pure GMP chitosan.

The KiOmedine®range is now distributed by Sigma-Aldrich for research purposes. Click here to order samples and find detailed information : Sigma-Aldrich website

For industrial customers, contact us